Rubicon Research IPO: Pharma Player Enters the Market!

Rubicon Research, a pharma company, is coming with its IPO (Initial Public Offering) on October 9, and it will close on October 13. The shares will list on the stock market on October 16. Price band: ₹461 – ₹485 per share Total IPO size: ₹1,377.5 crore Fresh issue: ₹500 crore (new shares, money goes to company) OFS (Offer For Sale): ₹877.5 crore (promoter selling shares) Where the money will go? • Around ₹310 crore to repay loans (reduce debt). • Rest for acquisitions, expansion, and general use. About the company: Rubicon makes pharma formulations (tablets, capsules, drug-device products) mainly for the US and regulated markets. • Strong focus on R&D (has USFDA-approved labs in India & Canada). • Recently bought a plant from Alkem Labs in Madhya Pradesh for ₹149 crore. • Has 2 manufacturing plants in India with top-level approvals (USFDA, WHO-GMP, Health Canada). Shareholding: General Atlantic Singapore is the biggest promoter with 52% stake. Some other promoters are from the Pilgaonkar and Sancheti families. IPO Reservation: • 75% for big institutions (QIBs) • 15% for high-net-worth individuals • 10% for retail investors Positives: • Strong R&D focus with approvals from global regulators. • Expanding manufacturing capacity (new plant from Alkem). • Reducing debt, which can improve financial health. • Presence in high-value US market. Risks: • Heavy reliance on US market (any USFDA issues can hurt). • Promoter is selling a large stake (OFS of ₹877.5 crore) – may signal partial exit. • Pharma industry is competitive and margin pressures are high. • Debt still exists even after repayment. Summary: Rubicon is a pharma company with global approvals, strong R&D, and focus on growth. But, promoter selling big shares and US dependence are risks. Investors should check both sides before applying.